Drug Trial Radar · NCT05638282
A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants
Last checked: Nov 19, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Feb 15, 2023
Primary completion
Jun 27, 2023
Study completion Jun 27, 2023
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Dec 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the drug levels, safety, and tolerability of cendakimab in healthy male and female Chinese participants.
Conditions
- Healthy Participants
Interventions
CendakimabDrug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Serum Concentration (Cmax)Time frame: Predose and at multiple timepoints (up to 105 days) after dosing
- Area Under the Serum Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC(0-T))Time frame: Predose and at multiple timepoints (up to 105 days) after dosing
- Area Under the Serum Concentration-time Curve from Time Zero Extrapolated to Infinite Time (AUC(INF))Time frame: Predose and at multiple timepoints (up to 105 days) after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.